What is ARS Pharmaceuticals, Inc.'s market cap?

ARS Pharmaceuticals, Inc. (SPRY) has a market capitalization of $782.5M and trades on NASDAQ.

What is ARS Pharmaceuticals, Inc.'s revenue and profitability?

ARS Pharmaceuticals, Inc. generated $99.0M in trailing twelve-month revenue with a net loss of $198.0M, representing a net margin of -200.0%, with free cash flow of -$175.3M. These figures are based on the Q1 2026 filing.

Who are ARS Pharmaceuticals, Inc.'s competitors?

ARS Pharmaceuticals, Inc.'s key competitors include Amneal Pharmaceuticals, Viatris Inc., Teva Pharmaceutical Industries Ltd., and others. These companies compete in similar markets and product categories.

Who does ARS Pharmaceuticals, Inc. partner with?

ARS Pharmaceuticals, Inc.'s notable partners include ALK-Abelló, Alfresa Holdings, CSL Seqirus, and others.

Where is ARS Pharmaceuticals, Inc. headquartered?

ARS Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 24 people. It has been publicly traded since 2022.

ARS Pharmaceuticals, Inc.

SPRY

ARS Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of needle-free intranasal epinephrine delivery systems.

Market cap

$782.51M-55.7%

Revenue$99.0M+1.9%

Net income-$198.0M-1,165%

Free cash flow-$175.3M-733%

EPS (diluted)-$2.01-1,082%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 15, 2026

Revenue$22.7MBeat by $481.0K EPS-$0.61Miss by $0.08

Read the full report

Next report

Aug 12, 2026 (in a month)

Revenue estimate$31.3M

EPS estimate-$0.48

Financials

Q1 2026

Income statement

See full

Revenue$22.7M+184%

Operating income-$60.1M-61.8%

Net income-$60.6M-78.6%

EPS (diluted)-$0.61-74.3%

Balance sheet

See full

Cash & equivalents$24.3M-39.0%

Total debt$96.5M+132,122%

Total equity$61.3M-73.2%

Total assets$287.6M-12.1%

Cash flow

See full

Operating cash flow-$44.9M-10.3%

CapEx--100%

Free cash flow-$44.9M-10.1%

Valuation & ratios

Valuation

See full

Market cap$782.51M-55.7%

Enterprise value$854.71M-47.5%

P/S7.9×-7.0×

Profitability

See full

Operating margin-204.5%—

Net margin-200%-219pp

FCF margin-177.1%-206pp

Returns & leverage

See full

Return on equity-136.4%-144pp

Debt / equity1.6×+1.6×

Current ratio4.9×-6.1×

Segments

By geography

See full

Non Us$2.5M—

Competitors

By market cap

Viatris$19.0B+76.2%

Amneal Pharmaceuticals, Inc.$5.4B+106%

AMP

Amphastar Pharmaceuticals$838.6M-22.2%

ARS Pharmaceuticals, Inc.$782.5M-53.4%

Neuropace, Inc.$578.6M+72.6%

Aquestive Therapeutics, Inc.$532.0M+44.8%

Milestone Pharmaceuticals$163.1M+40.6%

Vistagen Therapeutics, Inc.$10.2M-84.1%

By revenue growth

Neuropace, Inc.+18.1%

Amneal Pharmaceuticals, Inc.+7.6%

ARS Pharmaceuticals, Inc.+1.9%

Viatris+1.6%

AMP

Amphastar Pharmaceuticals-1.4%

Aquestive Therapeutics, Inc.-7.3%

By net margin

AMP

Amphastar Pharmaceuticals11.0%-8.4pp

Amneal Pharmaceuticals, Inc.4.01%+4.5pp

Viatris-2.04%+24.4pp

Neuropace, Inc.-21.67%+7.8pp

Aquestive Therapeutics, Inc.-137.08%-37.1pp

ARS Pharmaceuticals, Inc.-200.0%-184pp

Profile

ARS Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of needle-free intranasal epinephrine delivery systems. Its lead product, neffy, provides a non-invasive alternative to traditional injectable treatments for Type I allergic reactions, including anaphylaxis. The company aims to address unmet needs in the allergy market by improving patient compliance and reducing the needle-related anxiety associated with emergency epinephrine administration.

Competitive position

ARS Pharmaceuticals holds a first-mover advantage as the provider of the first and only FDA-approved needle-free epinephrine product, challenging a decades-old reliance on injectable delivery methods.

GeographiesUnited States, European Union, United Kingdom, Japan, China, Australia, Canada

Customer segmentsPatients, Healthcare Providers, Retail Pharmacies

Business modelProduct-based, Licensing and Royalties

SuppliersEpinephrine active pharmaceutical ingredient suppliers, Intravail absorption enhancer licensors, Specialized medical device manufacturers

CustomersWholesale pharmaceutical distributors, Retail pharmacies, Hospitals and emergency clinics, Direct-to-consumer patients

CountryUnited States of America

Listed2022

Employees24.0

CEORichard E. Lowenthal

SectorHealthcare

IndustryBiotechnology

Websitears-pharma.com

FilingsSEC EDGAR

Ask your AI about ARS Pharmaceuticals, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ARS Pharmaceuticals, Inc.'s market cap?: ARS Pharmaceuticals, Inc. (SPRY) has a market capitalization of $782.5M and trades on NASDAQ.
What is ARS Pharmaceuticals, Inc.'s revenue and profitability?: ARS Pharmaceuticals, Inc. generated $99.0M in trailing twelve-month revenue with a net loss of $198.0M, representing a net margin of -200.0%, with free cash flow of -$175.3M. These figures are based on the Q1 2026 filing.
Who are ARS Pharmaceuticals, Inc.'s competitors?: ARS Pharmaceuticals, Inc.'s key competitors include Amneal Pharmaceuticals, Viatris Inc., Teva Pharmaceutical Industries Ltd., and others. These companies compete in similar markets and product categories.
Who does ARS Pharmaceuticals, Inc. partner with?: ARS Pharmaceuticals, Inc.'s notable partners include ALK-Abelló, Alfresa Holdings, CSL Seqirus, and others.
Where is ARS Pharmaceuticals, Inc. headquartered?: ARS Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 24 people. It has been publicly traded since 2022.